Literature DB >> 18248959

Decreased entorhinal cortex volumes in schizophrenia.

Monica Baiano1, Cinzia Perlini, Gianluca Rambaldelli, Roberto Cerini, Nicola Dusi, Marcella Bellani, Giorgia Spezzapria, Amelia Versace, Matteo Balestrieri, Roberto Pozzi Mucelli, Michele Tansella, Paolo Brambilla.   

Abstract

BACKGROUND: The entorhinal cortex is located in the medial temporal lobe and is involved in memory and learning. Previous MRI studies reported conflicting findings in schizophrenia, showing normal or reduced entorhinal size.
OBJECTIVES: To explore entorhinal cortex volumes in a large sample of patients with schizophrenia recruited from the geographically defined catchment area of South Verona (i.e. 100,000 inhabitants). We also investigated the size of hippocampus as part of the medial temporal lobe.
METHODS: 70 patients with schizophrenia and 77 normal controls underwent a session of MRI (TR=2060 ms, TE=3.9 ms, slice thickness=1.25 mm). Entorhinal and hippocampal volumes were explored using the Brains2 software.
RESULTS: A significant group effect was found for total entorhinal cortex but not for hippocampus, with patients suffering from schizophrenia having smaller entorhinal volumes compared to normal subjects (F=6.24, p=0.01), particularly on the right side (F=9.76, p=0.002). Also, the laterality index for entorhinal cortex was higher in normal individuals than in patients with schizophrenia (F=5.45, p=0.02).
CONCLUSIONS: Consistent with some of the previous reports, our study confirmed the presence of abnormally decreased entorhinal volumes, particularly on the right side, in a large number of patients with schizophrenia and also found altered asymmetry. This may play a major role in the psychopathology and cognitive disturbances of the disease. Future longitudinal MRI studies including high-risk subjects and drug-free, first-episode patients are crucial to further understand whether entorhinal cortex shrinkage is already present at the onset of the illness or appears as a consequence of the illness.

Entities:  

Mesh:

Year:  2008        PMID: 18248959     DOI: 10.1016/j.schres.2007.11.035

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  26 in total

1.  The impact of schizophrenia on frontal perfusion parameters: a DSC-MRI study.

Authors:  Denis Peruzzo; Gianluca Rambaldelli; Alessandra Bertoldo; Marcella Bellani; Roberto Cerini; Marini Silvia; Roberto Pozzi Mucelli; Michele Tansella; Paolo Brambilla
Journal:  J Neural Transm (Vienna)       Date:  2011-01-04       Impact factor: 3.575

2.  Psychopathological correlates of the entorhinal cortical shape in schizophrenia.

Authors:  C Christoph Schultz; Kathrin Koch; Gerd Wagner; Martin Roebel; Claudia Schachtzabel; Igor Nenadic; Carsten Albrecht; Jürgen R Reichenbach; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11-07       Impact factor: 5.270

3.  Thalamic-insular dysconnectivity in schizophrenia: evidence from structural equation modeling.

Authors:  Corrado Corradi-Dell'Acqua; Luisa Tomelleri; Marcella Bellani; Gianluca Rambaldelli; Roberto Cerini; Roberto Pozzi-Mucelli; Matteo Balestrieri; Michele Tansella; Paolo Brambilla
Journal:  Hum Brain Mapp       Date:  2011-04-11       Impact factor: 5.038

4.  Classification of schizophrenia using feature-based morphometry.

Authors:  U Castellani; E Rossato; V Murino; M Bellani; G Rambaldelli; C Perlini; L Tomelleri; M Tansella; P Brambilla
Journal:  J Neural Transm (Vienna)       Date:  2011-09-09       Impact factor: 3.575

5.  Histamine facilitates GABAergic transmission in the rat entorhinal cortex: Roles of H1 and H2 receptors, Na+ -permeable cation channels, and inward rectifier K+ channels.

Authors:  Nicholas I Cilz; Saobo Lei
Journal:  Hippocampus       Date:  2017-02-28       Impact factor: 3.899

Review 6.  Extracellular matrix proteomics in schizophrenia and Alzheimer's disease.

Authors:  Manveen K Sethi; Joseph Zaia
Journal:  Anal Bioanal Chem       Date:  2016-09-06       Impact factor: 4.142

Review 7.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

8.  Temporal Lobe Volume Decrements in Psychosis Spectrum Youths.

Authors:  David R Roalf; Megan Quarmley; Monica E Calkins; Theodore D Satterthwaite; Kosha Ruparel; Mark A Elliott; Tyler M Moore; Ruben C Gur; Raquel E Gur; Paul J Moberg; Bruce I Turetsky
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

9.  Neuropathological and Reelin deficiencies in the hippocampal formation of rats exposed to MAM; differences and similarities with schizophrenia.

Authors:  Julien Matricon; Alfredo Bellon; Helge Frieling; Oussama Kebir; Gwenaëlle Le Pen; Frédéric Beuvon; Catherine Daumas-Duport; Thérèse M Jay; Marie-Odile Krebs
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

10.  Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study.

Authors:  P Brambilla; C Perlini; P Rajagopalan; P Saharan; G Rambaldelli; M Bellani; N Dusi; R Cerini; R Pozzi Mucelli; M Tansella; P M Thompson
Journal:  Br J Psychiatry       Date:  2013-01       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.